Employees: 371
Size REGENXBIO (RGNX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $480M, the 2697th largest of 3,085 United States companies the cockpit tracks. Shares closed at $7.26 on 18 Nov 2026.
Performance Over six months the shares gained 21.6%, against -14.4% for the median peer and -2.2% for the United States market (cap-weighted) — 5th highest of 21 in its peer set.
Growth Revenue fell 4.6% over the last twelve months (peer median +11.0%); the operating margin is -120.4% (peer median 10.9%).
Valuation It trades at 3.1× enterprise value to sales against a peer median of 4.3× (8th cheapest of 20).
Capital Return on invested capital runs 107.5 points below its cost of capital (9.3% WACC).
Short interest Short interest is 15.4% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $154M | $170M | $83.3M | $90.2M | $113M |
| Revenue growth | — | +105% | -8% | -20% | — |
| Gross profit | $120M | $135M | $33.5M | $35.7M | $45.3M |
| EBITDA | -$170M | -$146M | -$215M | -$251M | -$250M |
| Net income | -$175M | -$194M | -$227M | -$263M | -$280M |
| Free cash flow | -$155M | -$126M | -$176M | -$228M | -$238M |
| Capital expenditure | $2.70M | $2.41M | $2.44M | $9.96M | $30.7M |
| Total debt | $252M | $261M | $142M | $89.3M | $94.8M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RGNX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -1.9% | -3.4% | 9th highest of 21 |
| 6-month return | +21.6% | -14.4% | 5th highest of 21 |
| Distance from 52-week high | -55.2% | -36.8% | 5th lowest of 21 |
| Revenue growth (TTM) | -4.6% | +11.0% | 6th lowest of 21 |
| Operating margin | -120.4% | 10.9% | 2nd lowest of 20 |
| EV / Sales | 3.1× | 4.3× | 8th cheapest of 20 |
| ROIC minus cost of capital | -107.5 pp | -2.6 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |